Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML-Reference-Cited by-同舟云学术

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML

Published:2009-03-19 Issue:7 Volume:23 Page:1343-1345
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Tefferi A,Lim K-H,Abdel-Wahab O,Lasho T L,Patel J,Patnaik M M,Hanson C A,Pardanani A,Gilliland D G,Levine R L

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu200959.pdf

Reference6 articles.

1. Delhommeau F, Dupont S, James C, Masse A, le Couedic JP, Valle VD et al. TET2 is a novel tumor suppressor gene inactivated in myeloproliferative neoplasms: identification of a Pre-JAK2 V617F event. ASH Annual Meeting Abstracts 2008; 112: lba-3. Late-Breaking Abstract.

2. Tefferi A, Pardanani A, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009, advance online publication, 5 March 2009; doi:10.1038/ leu.2009.47.

3. Tefferi A, Levine RL, Lim K-H, Abdel-Wahab O, Lasho TL, Patel J et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009, advance online publication, 5 March 2009; doi:10.1038/ leu.2009.37.

4. Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.

5. Jaffe ES, Harris NL, Stein H, Vardiman JW . World Health Organization Classification of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 1–351.

Cited by 229 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myelodysplastic Syndrome: Clinical Characteristics and Significance of Preclinically Detecting Biallelic Mutations in the TET2 Gene;Life;2024-05-16

2. Chronic myelomonocytic leukemia: 2024 update on diagnosis, risk stratification and management;American Journal of Hematology;2024-03-07

3. Biological insights into the role of TET2 in T cell lymphomas;Frontiers in Oncology;2023-09-29

4. Neurological adverse effects of chimeric antigen receptor T-cell therapy;Expert Review of Clinical Immunology;2023-09-04

5. Comparative analysis of Tet2 catalytic-deficient and knockout bone marrow over time;Experimental Hematology;2023-08